



PRESS CLIPPING SHEET

PUBLICATION:	Daily News Egypt
DATE:	21-June-2022
COUNTRY:	Egypt
CIRCULATION:	80,000
TITLE:	Novartis, Sandoz demonstrated pivotal impact of public-
	private partnerships to strengthen healthcare sustainability
PAGE:	02
ARTICLE TYPE:	Agency-Generated News
REPORTER:	Staff Report
AVE:	10,000

Novartis, Sandoz demonstrate pivotal impact of public-private partnerships to strengthen healthcare sustainability

Egyptian healthcare system achieves revolutionary progress, we are privileged to support this ongoing transformation through pivotal partnership initiatives, says Jamal Habash

Novartis Egypt, together with Sandoz Egypt, its division for generics and biosimilars, partnered with health authorities and industry stakehold-ers to support the success of Africa Health ExCon, the region's first all-encompassing platform to position the continent as a hub for health in-novation and trade novation and trade.

Organized by the Egyptian Author-ity for Unified Procurement (UPA).Af-rica Health ExCon was held under the patronage of President Abdel Fattah Al-Sisi between 5-7 June, bringing to-At sain between 3-7 Julie, Bringing Go-gether the region's key statkeholders to lay the blueprint for progress in health-care, transforming pledges into action. "Driven by our commitment to-wards patients, Novartis Egypt is incredibly proud of its long-standing with the same state of the statement

increationy proud of its long-standing collaboration with the Egyptian gov-ernment and healthcare authorities. As a global healthcare leader vested in reimagining medicine, we believe that only via effective public-private collaboration can we harness our cu-

ulative strengths to drive sustain able value for people and systems," said Jamal Habash, Novartis Egypt

said jamai Habash, Novartis Egypt CPO and Country President. "The Egyptian healthcare system has achieved revolutionary progress and we are privileged to support this ongoing transformation through piv-otal partnership initiatives reshaping otal partnersnip initiatives resnaping the country's healthcare ecosystem and paving the way to realizing Egypt Vision 2030. Our three divisions helped transform the lives of over 10 million Egyptian patients across withing the papertie means including multiple therapeutic areas including cardiovascular disease (CVD), cell and gene therapy, diabetes, respiratory, and bone and pain and we ceaselessly work with healthcare authorities to accelerate access to innovation. We continue to collaborate with the anchor presidential 100 Million Health

campaign with a special focus on CVD, the number one killer worldwide, and we are steadfast in our commitment to fight atherosclerotic cardiovascu-



lar disease (ASCVD) in partnership with all stakeholders to ensure that every patient receives the treatment they need." he added.

"Leaving no one behind' is at the core of the United Nations Sustainable Development Goals (SDGs), and Egypt Development Goals (SDGs), and Egypt - as part of its Vision 2030 - is commit-ted to building partnerships grounded on common objectives. In healthcare, the government has driven unprec-edented progress expanding access to

a la la top-of-the-line services, while rebuilding the sector with the introduction of universal health insurance alongside of universal health insurance, alongside large-scale screening and treatment initiatives," said Hossam Abdel Ghaf-far, Secretary General of the Supreme

Tar. Secretary General of the Supreme Council of University Hospitals and Official spokesperson for the Ministry of Health and Population. "The scale and scope of advances that Egypt has achieved in healthcare can only be described as a dream come

true and I am proud that Novartis's commitment to Egyptian patients and

commitment to Egyptian patients and partnership with the government has played an integral role." Sheerif Amin, Novartis Oncology General Manag-er, said. "When it comes to women's health. breast cancer tops the agenda as the most common kind of cancer to affect women in Egypt. At No-vartis we tackle the tough questions and challenge the status quo, we col-laborate to serve patient populations where the needs are high; and breast cancer is a case in point; in Egypt breast cancer accounts for almost breast cancer accounts for almost one in three (32%) of all cancer cases diagnosed.We are proud to be a main partner of the Presidential Initiative for Women's Health and the Egyptian government on diverse initiatives as part of an ambitious national plan to part of an ambitious national plan to elevate cancer care and control, with breast cancer defining the first phase of the agenda." "Healthcare system sustainability is the key to achieve universal access As a

global leader in generic pharmaceuticals and biosimilars our purpose is to accel-erate access by providing high-quality affordable treatments," said Sameh El

affordable treatments," said Sameh El Bagoury, Sandoz Egypt Country Head. "Today, healthcare systems world-wide face more pressure than ever before, in Africa these challenges are further compounded by a unique set further compounded by a unque set of challenges that demand revolution-ary approaches for effective solutions. Biosimilars are integral to that solution, they lay the foundations for sustainable healthcare while offering patients a new realm of possibility.We are proud with our recent launch of 'Act4Biosimilars' our recent launch of 'Act+Biosimilars' a global initiative that aims to increase patient access to advanced medicines by facilitating greater approvability ac-cessibility acceptability and affordabil-ity. In our quest to ensure that no pa-tient is left behind, we will continue to work with stakeholders across Africa to drive action designed to integrate affordabi treatment options within healthcare systems."